Related Experiment Video
Updated: Apr 10, 2026
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Dual TNF-α/IL-12p40 Interference as a Strategy to Protect Against Colitis Based on miR-16 Precursors With Macrophage
Zhen Huang1, Junting Ma1, Mengjie Chen1
1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
Abstract:
Cytokines are central components of the mucosal inflammatory responses that take place during the development of Crohn's disease. Cell-specific combination therapies against cytokines may lead to increased efficacy and even reduced side effects. Therefore, a colonic macrophage-specific therapy using miR-16 precursors that can target both TNF-α and IL-12p40 was tested for its efficacy in experimental colitic mice. Galactosylated low molecular weight chitosan (G-LMWC) associated with miR-16 precursors were intracolonically injected into mice. The cellular localization of miR-16 precursors was determined. The therapeutic effects and possible mechanism were further studied in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitic mice. The results show that specific upregulation of miR-16 level in colonic macrophages significantly reduces TNF-α and IL-12p40 expression, which could suppress the associated mucosal inflammation and ultimately result in the relief of colitic symptoms. This strategy, based on the dual silencing of colonic macrophage-specific cytokines, represents a potential therapeutic approach that may be valuable for colitis therapy.
Insights
A novel therapy using miR-16 precursors targets specific cytokines in colon macrophages to reduce inflammation. This approach shows promise for treating Crohn
Area of Science:
- Immunology
- Gastroenterology
- Biotechnology
Background:
- Cytokines are key drivers of mucosal inflammation in Crohn's disease.
- Targeting specific cytokines offers potential for more effective and safer therapies.
- Macrophage-specific therapies can enhance treatment efficacy and reduce side effects.
Purpose of the Study:
- To evaluate a colonic macrophage-specific therapy using miR-16 precursors.
- To assess the dual targeting of Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-12p40 (IL-12p40).
- To investigate the therapeutic potential in a mouse model of colitis.
Main Methods:
- Intracolonic injection of galactosylated low molecular weight chitosan (G-LMWC) associated with miR-16 precursors.
- Determination of cellular localization of miR-16 precursors.
- Assessment of therapeutic effects in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitic mice.
Main Results:
- Specific upregulation of miR-16 in colonic macrophages significantly reduced TNF-α and IL-12p40 expression.
- Suppression of mucosal inflammation and relief of colitis symptoms observed.
- Demonstrated successful cellular localization and therapeutic impact of the G-LMWC-miR-16 complex.
Conclusions:
- Colonic macrophage-specific dual silencing of TNF-α and IL-12p40 via miR-16 precursors is effective in experimental colitis.
- This strategy represents a potential therapeutic approach for colitis.
- The findings suggest a valuable new avenue for Crohn's disease treatment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...